NEWNAN, Ga., Dec. 16 /PRNewswire/ -- CeloNova BioSciences, Inc., announced
today that it has received 510(k) marketing clearance from the U.S. Food and
Drug Administration (FDA) for Embozene(TM) Color-Advanced Microspheres which
are indicated for the treatment of hypervascularized tumors (tumors with a
large number of blood vessels in many locations) and arteriovenous
malformations (defects in the circulatory system). U.S. commercial sales of
Embozene(TM) Microspheres will begin immediately.

Embozene(TM) Microspheres are the first and only microspheres to be color-
enhanced with a different color for each size for increased procedural safety,
efficiency and visibility. They are also available in a wider range of sizes
than any other spherical embolic on the market. They are available in 40
micrometers, 100 micrometers, 250 micrometers, 400 micrometers, 500
micrometers, 700 micrometers, and 900 micrometers sizes in 1 ml and 2 ml
pre-filled syringes and vials. CeloNova plans to submit a supplemental 510(k)
to the FDA to add three additional sizes, 75 micrometers, 1100 micrometers and
1300 micrometers, for a total of ten sizes including the smallest and the
largest microspheres available for endovascular therapy. CeloNova is the only
Company that provides this complete range of products.

CeloNova's Embozene(TM) Microspheres consist of a hydrogel core and an
exterior shell made from Polyzene(R)-F, CeloNova's proprietary polymer which
is known to be anti-inflammatory and bacterial-resistant. Four design features
distinguish Embozene(TM) Microspheres from other spherical embolics:
biocompatibility, precise calibration, stable suspension, and structural
stability. Embozene(TM) Microspheres are precisely calibrated, they retain
their shape after passing through a catheter, and they can stay in suspension
for an extended time. The unique color enhancement of the microspheres and
finely calibrated sizes make selection easy, efficient, and precise for the
operator. The result is an embolic microsphere that provides accurate and
complete vessel occlusion.

Embolization is a minimally invasive procedure used to control or prevent
abnormal bleeding, to shrink tumors by blocking the blood vessels that supply
them, and to block off blood vessel malformations. Physicians use enhanced
imaging techniques to visualize the blood vessel, then insert and advance a
catheter to the treatment site. The embolic agent is then released into the
catheter and positioned within the blood vessel or malformation to block the
target vessel permanently.

"Embozene Microspheres are an innovative advance in embolic technology
that has been well received outside the U.S.," said John C. Lipman, MD, FSIR,
Founder and CEO of the Atlanta Interventional Institute and Director of the
Center for Image-Guided Medicine at Emory-Adventist Hospital Atlanta.
"Intuitively, a polymer that is anti-inflammatory and that provides more
finely calibrated bead sizes, shape integrity, prolonged suspension, and has a
unique color-coded selection system that makes for more efficient procedures,
will appeal to physicians as well as patients. Embozene(TM) Microspheres
maintain suspension better than any other embolic I've seen," said Dr. Lipman.
"I'm looking forward to using this therapy in my practice."

"From the outset, we took a different approach to developing our
Embozene(TM) Microspheres by asking physicians and medical scientists for the
qualities and characteristics that the ideal embolic device should have," said
Thomas A. Gordy, President and Chief Executive Officer, CeloNova BioSciences,
Inc. "Then, we engineered Embozene(TM) Microspheres to have those properties,
which are made even better with Polyzene(R)-F, our proprietary polymer.
Polyzene(R)-F helps make our leading-edge technology better."

For more information about CeloNova BioSciences, visit www.celonova.com.
To place an order for Embozene(TM) Microspheres, call 888-388-3888 to reach
your local sales representative or e-mail info@celonova.com.

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc.,
is a developer of novel medical devices that are then enhanced by one of the
Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly
lubricious, anti-inflammatory, and bacterial-resistant making it an ideal
surface treatment for implanted medical devices. The Company's current
products include its Embozene(TM) Color-Advanced Microspheres and the
CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other
innovative devices are currently in the company's developmental pipeline. For
more information, please visit www.celonova.com.

About Polyzene(R)-F

Polyzene(R)-F is a synthesized inorganic chemical compound with an
extensive array of bioscience and industrial applications that can be applied
as a surface coating ranging in thickness from less than 50 nanometers to more
than 200 nanometers. The polymer can be applied to or mixed with other
substances to allow for a diverse range of applications on a multitude of
substrates, including other polymers, metals and ceramics. Polyzene(R)-F can
be customized for the desired application and applied in a variety of ways
including as a coating, extrusion, weaving, or electro-spinning. The base
substrate will be endowed with the properties of the polymer.

(Date:12/8/2016)... Research and Markets has announced the addition ... ... The global chromatography market to grow at a CAGR of ... has been prepared based on an in-depth market analysis with inputs from ... over the coming years. The report also includes a discussion of the ...

(Date:12/8/2016)... TEMPE, Ariz., Dec. 8, 2016 Economic growth in ... nation,s purchasing and supply management executives in their December ... of the economic recovery that began in mid-2009, as ... On Business ® . The manufacturing sector is ... increase in 16 manufacturing industries, and the non-manufacturing sector ...

(Date:12/8/2016)... 8, 2016 Noom, Inc., the leader in ... enterprise customers only when their members achieve real health ... wellness sector, which typically charges for arbitrary enrollment, participation ... The ... technology with the empathy of live human coaches to ...